{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Dallas&page=8&state=Texas", "query": { "state": "Texas", "city": "Dallas", "page": 8 }, "page_size": 10 }, "pagination": { "page": 8, "page_size": 10, "total_count": 13764, "total_pages": 1377, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Dallas&page=9&state=Texas&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Dallas&page=7&state=Texas&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-02T23:39:31.537Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00016965", "title": "BMS-247550 in Treating Patients With Advanced Pancreatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Cancer" ], "interventions": [ { "name": "ixabepilone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "2001-07", "completion_date": "2006-04", "has_results": false, "last_update_posted_date": "2013-06-24", "last_synced_at": "2026-11-02T23:39:31.537Z", "location_count": 95, "location_summary": "Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 60 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00016965" }, { "nct_id": "NCT02603107", "title": "Study to Evaluate the Safety and Efficacy of Switching From Regimens Consisting of Boosted Atazanavir or Darunavir Plus Either Emtricitabine/Tenofovir or Abacavir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed HIV-1 Infected Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV-1 Infection" ], "interventions": [ { "name": "RTV", "type": "DRUG" }, { "name": "ATV", "type": "DRUG" }, { "name": "DRV", "type": "DRUG" }, { "name": "COBI", "type": "DRUG" }, { "name": "ATV/co", "type": "DRUG" }, { "name": "DRV/co", "type": "DRUG" }, { "name": "FTC/TDF", "type": "DRUG" }, { "name": "ABC/3TC", "type": "DRUG" }, { "name": "B/F/TAF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 578, "start_date": "2015-11-20", "completion_date": "2019-12-23", "has_results": true, "last_update_posted_date": "2020-12-29", "last_synced_at": "2026-11-02T23:39:31.537Z", "location_count": 63, "location_summary": "Phoenix, Arizona • Los Angeles, California • Newport Beach, California + 49 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02603107" }, { "nct_id": "NCT02855411", "title": "A Study To Evaluate The Safety And Efficacy Of PF-04958242 In Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cognitive Impairment Associated With Schizophrenia (CIAS)" ], "interventions": [ { "name": "PF-04958242", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Biogen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 35, "start_date": "2016-08-29", "completion_date": "2016-09-26", "has_results": true, "last_update_posted_date": "2020-01-09", "last_synced_at": "2026-11-02T23:39:31.537Z", "location_count": 16, "location_summary": "Garden Grove, California • Oceanside, California • Orange, California + 11 more", "locations": [ { "city": "Garden Grove", "state": "California" }, { "city": "Garden Grove", "state": "California" }, { "city": "Oceanside", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02855411" }, { "nct_id": "NCT06277934", "title": "A Study of RGT001-075 in Participants With Obesity or Overweight With Weight-Related Comorbidities", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Obesity" ], "interventions": [ { "name": "RGT001-075", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Regor Pharmaceuticals Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 73, "start_date": "2024-03-08", "completion_date": "2024-08-13", "has_results": false, "last_update_posted_date": "2025-08-07", "last_synced_at": "2026-11-02T23:39:31.537Z", "location_count": 10, "location_summary": "Los Angeles, California • Valparaiso, Indiana • Omaha, Nebraska + 7 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Valparaiso", "state": "Indiana" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "Vestal", "state": "New York" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT06277934" }, { "nct_id": "NCT00531427", "title": "Buprenorphine Transdermal System (BTDS) in Subjects w/Mod-sev Osteoarthritis (OA) Chronic Pain of Knee", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Pain", "Osteoarthritis of the Knee" ], "interventions": [ { "name": "Buprenorphine", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Purdue Pharma LP", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 567, "start_date": "2007-09", "completion_date": "2009-11", "has_results": true, "last_update_posted_date": "2012-09-10", "last_synced_at": "2026-11-02T23:39:31.537Z", "location_count": 87, "location_summary": "Mobile, Alabama • Chandler, Arizona • Phoenix, Arizona + 73 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00531427" }, { "nct_id": "NCT01031173", "title": "Treatment Protocol of Replagal for Patients With Fabry Disease", "overall_status": "NO_LONGER_AVAILABLE", "study_type": "EXPANDED_ACCESS", "phases": [], "conditions": [ "Fabry Disease" ], "interventions": [ { "name": "agalsidase alfa", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Shire", "sponsor_class": "INDUSTRY", "healthy_volunteers": null, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2021-05-24", "last_synced_at": "2026-11-02T23:39:31.537Z", "location_count": 25, "location_summary": "Tucson, Arizona • La Jolla, California • Los Angeles, California + 21 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Oakland", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01031173" }, { "nct_id": "NCT02578641", "title": "A Phase III Trial Evaluating Chemotherapy and Immunotherapy for Advanced Nasopharyngeal Carcinoma (NPC) Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Nasopharyngeal Carcinoma" ], "interventions": [ { "name": "autologous EBV specific Cytotoxic T cells", "type": "BIOLOGICAL" }, { "name": "combination IV gemcitabine and IV carboplatin (AUC2)", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Tessa Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 330, "start_date": "2014-07", "completion_date": "2022-02-28", "has_results": true, "last_update_posted_date": "2023-06-28", "last_synced_at": "2026-11-02T23:39:31.537Z", "location_count": 7, "location_summary": "Duarte, California • Sacramento, California • San Francisco, California + 4 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02578641" }, { "nct_id": "NCT04230122", "title": "A Study of LY3478006 in Healthy Participants", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "LY3478006 - IV", "type": "DRUG" }, { "name": "LY3478006 - SC", "type": "DRUG" }, { "name": "Placebo - IV", "type": "DRUG" }, { "name": "Placebo - SC", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 4, "start_date": "2020-02-17", "completion_date": "2020-06-04", "has_results": true, "last_update_posted_date": "2021-12-06", "last_synced_at": "2026-11-02T23:39:31.537Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04230122" }, { "nct_id": "NCT02114931", "title": "Long-term Safety and Efficacy of ABP 501 in Subjects With Moderate to Severe Rheumatoid Arthritis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Arthritis, Rheumatoid" ], "interventions": [ { "name": "ABP 501", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "81 Years", "sex": "ALL", "summary": "18 Years to 81 Years" }, "enrollment_count": 467, "start_date": "2014-04", "completion_date": "2016-04", "has_results": true, "last_update_posted_date": "2017-04-24", "last_synced_at": "2026-11-02T23:39:31.537Z", "location_count": 29, "location_summary": "Huntsville, Alabama • Peoria, Arizona • Scottsdale, Arizona + 26 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Covina", "state": "California" }, { "city": "El Cajon", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02114931" }, { "nct_id": "NCT03384745", "title": "A Phase 2b Study of the Efficacy, Safety, and Tolerability of M1095 (Sonelokimab) in Subjects With Moderate to Severe Psoriasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Psoriasis" ], "interventions": [ { "name": "M1095 (Sonelokimab)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Secukinumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bond Avillion 2 Development LP", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 313, "start_date": "2018-07-31", "completion_date": "2020-03-26", "has_results": true, "last_update_posted_date": "2021-08-03", "last_synced_at": "2026-11-02T23:39:31.537Z", "location_count": 11, "location_summary": "Birmingham, Alabama • San Diego, California • DeLand, Florida + 8 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "San Diego", "state": "California" }, { "city": "DeLand", "state": "Florida" }, { "city": "Sandy Springs", "state": "Georgia" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT03384745" } ] }